https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.12849
https://www.ncbi.nlm.nih.gov/pubmed/30707471?dopt=Abstract
Tetra-arsenic tetra-sulfide Ameliorates Lupus Syndromes by Inhibiting IL-17 producing Double Negative T cells.
Dermatol Ther
Tetra-arsenic tetra-sulfide Ameliorates Lupus Syndromes by Inhibiting IL-17 producing Double Negative T cells.
Dermatol Ther. 2019 Feb 01;:e12849
Authors: Zhao Y, Mu Z, Cai L, Liu X, Jun J, Zhang J
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease of uncertain etiology that affects multiple tissues and organs. Tetra-arsenic tetra-sulfide (As4 S4 ), a traditional Chinese medicine, is effective on acute promyelocytic leukemia with mild side effects. In our previous study, BXSB lupus-prone mice treated with As4 S4 has showed improved monocytosis, decreased serum interleukin-6 (IL-6) and suppressed skin, liver and renal lesions with well-tolerance. In this study, we explored the effect and mechanism of As4 S4 on the MRL/lpr mice. MRL/lpr and wild MRL/MpJ mice were divided into control and As4 S4 treatment groups and dosed with As4 S4 or placebo for 8 weeks. We found that As4 S4 prevented the skin, renal and lung lesions of MRL/lpr mice. As4 S4 significantly decreased the double negative T (DN T) cells and reduced the serum levels of IL-17, IL-10, and antinuclear antibodies (ANA) titer. Further results revealed that the FasL was decreased, and activated caspases elevated in DN T cells in As4 S4 treated MRL/lpr mice. Taken together, As4 S4 could selectively suppresses DN T cells by inducing apoptosis. It also reduced inflammatory cytokines IL-17, which may be produced by DN T cells. As4 S4 may represent a new therapy for SLE. This article is protected by copyright. All rights reserved.
PMID: 30707471 [PubMed – as supplied by publisher]
PubMed:30707471
